Download presentation
Presentation is loading. Please wait.
Published byDewi Rachman Modified over 6 years ago
1
Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms
4
Overview
5
Predictors for Disease Responsiveness to Novel Agents
6
Predictors for Disease Responsiveness to Novel Agents (cont)
7
Predictors for Disease Responsiveness With Idelalisib
8
Predictors for Disease Responsiveness With Ibrutinib
9
R/R CLL: Ibrutinib
10
R/R CLL: Venetoclax
11
Treatment Considerations: Del17p or TP53mut
12
Resistant Subclones Precede Relapse During Ibrutinib Therapy
13
Treatment Considerations: Del17p or TP53mut (cont)
14
Clinicopathological Features and Outcomes of Progression With Venetoclax
15
Molecular Basis for Relapse or Progression on Idelalisib
16
Individualizing Therapy in Challenging Cases
17
Patients With Del17p or TP53mut
18
Treatment of R/R CLL in Elderly Patients
19
RESONATE and RESONATE-2 Studies With Ibrutinib: Adverse Events by Age
20
Treatment of R/R CLL in Elderly Patients (cont)
21
Pooled Analysis of Venetoclax Efficacy in Patients With R/R CLL
22
Bulky Disease
23
Bulky Disease: del11q
24
Venetoclax Monotherapy After Ibrutinib or Idelalisib
25
Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax
26
Treatment Intolerance
27
Role of Allogeneic HSCT in R/R CLL
28
Richter Syndrome: Emerging Treatment Options
29
Combined Immune Approaches
30
Combination Therapy: Addition of Oral Small Molecules to Chemoimmunotherapy
31
Concluding Remarks
32
Concluding Remarks (cont)
33
Abbreviations
34
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.